Meropenem/vaborbactam

EN Texte en anglais Pas encore d'article dans ta langue : extrait en anglais.

Meropenem/vaborbactam, sold under the brand name Vabomere among others, is a combination medication used to treat complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia. It contains meropenem, a beta-lactam antibiotic; and vaborbactam, a beta-lactamase inhibitor. It is given by injection into a vein. Common side effects include headache, inflammation at the site of injection, nausea, diarrhea, liver inflammation, and low blood potassium. Severe side effects may include anaphylaxis, seizures, and Clostridioides difficile-associated diarrhea. It is unclear if use during pregnancy is safe. Meropenem works by blocking the construction of the bacterial cell wall while vaborbactam blocks the breakdown of meropenem by some beta-lactamases. The combination was approved for medical use in the United States in 2017, in the European Union in 2018, and in Canada in December 2024. It is on the World Health Organization's List of Essential Medicines.